461 related articles for article (PubMed ID: 11130383)
1. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
Narod SA; Brunet JS; Ghadirian P; Robson M; Heimdal K; Neuhausen SL; Stoppa-Lyonnet D; Lerman C; Pasini B; de los Rios P; Weber B; Lynch H;
Lancet; 2000 Dec; 356(9245):1876-81. PubMed ID: 11130383
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.
Gronwald J; Tung N; Foulkes WD; Offit K; Gershoni R; Daly M; Kim-Sing C; Olsson H; Ainsworth P; Eisen A; Saal H; Friedman E; Olopade O; Osborne M; Weitzel J; Lynch H; Ghadirian P; Lubinski J; Sun P; Narod SA;
Int J Cancer; 2006 May; 118(9):2281-4. PubMed ID: 16331614
[TBL] [Abstract][Full Text] [Related]
3. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
Schrag D; Kuntz KM; Garber JE; Weeks JC
JAMA; 2000 Feb; 283(5):617-24. PubMed ID: 10665701
[TBL] [Abstract][Full Text] [Related]
4. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
[TBL] [Abstract][Full Text] [Related]
5. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Gronwald J; Robidoux A; Kim-Sing C; Tung N; Lynch HT; Foulkes WD; Manoukian S; Ainsworth P; Neuhausen SL; Demsky R; Eisen A; Singer CF; Saal H; Senter L; Eng C; Weitzel J; Moller P; Gilchrist DM; Olopade O; Ginsburg O; Sun P; Huzarski T; Lubinski J; Narod SA;
Breast Cancer Res Treat; 2014 Jul; 146(2):421-7. PubMed ID: 24951267
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
Eisen A; Lubinski J; Klijn J; Moller P; Lynch HT; Offit K; Weber B; Rebbeck T; Neuhausen SL; Ghadirian P; Foulkes WD; Gershoni-Baruch R; Friedman E; Rennert G; Wagner T; Isaacs C; Kim-Sing C; Ainsworth P; Sun P; Narod SA
J Clin Oncol; 2005 Oct; 23(30):7491-6. PubMed ID: 16234515
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Reding KW; Bernstein JL; Langholz BM; Bernstein L; Haile RW; Begg CB; Lynch CF; Concannon P; Borg A; Teraoka SN; Törngren T; Diep A; Xue S; Bertelsen L; Liang X; Reiner AS; Capanu M; Malone KE;
Breast Cancer Res Treat; 2010 Sep; 123(2):491-8. PubMed ID: 20135344
[TBL] [Abstract][Full Text] [Related]
8. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
Narod SA; Sun P; Ghadirian P; Lynch H; Isaacs C; Garber J; Weber B; Karlan B; Fishman D; Rosen B; Tung N; Neuhausen SL
Lancet; 2001 May; 357(9267):1467-70. PubMed ID: 11377596
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.
Xu L; Zhao Y; Chen Z; Wang Y; Chen L; Wang S
Breast Cancer; 2015 Jul; 22(4):327-34. PubMed ID: 26022977
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.
King MC; Wieand S; Hale K; Lee M; Walsh T; Owens K; Tait J; Ford L; Dunn BK; Costantino J; Wickerham L; Wolmark N; Fisher B;
JAMA; 2001 Nov; 286(18):2251-6. PubMed ID: 11710890
[TBL] [Abstract][Full Text] [Related]
11. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
Metcalfe KA; Birenbaum-Carmeli D; Lubinski J; Gronwald J; Lynch H; Moller P; Ghadirian P; Foulkes WD; Klijn J; Friedman E; Kim-Sing C; Ainsworth P; Rosen B; Domchek S; Wagner T; Tung N; Manoukian S; Couch F; Sun P; Narod SA;
Int J Cancer; 2008 May; 122(9):2017-22. PubMed ID: 18196574
[TBL] [Abstract][Full Text] [Related]
12. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
13. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Lynch HT; Tung N; Armel S; Senter L; Singer CF; Fruscio R; Couch F; Weitzel JN; Karlan B; Foulkes WD; Moller P; Eisen A; Ainsworth P; Neuhausen SL; Olopade O; Sun P; Gronwald J; Narod SA;
Breast Cancer Res Treat; 2019 Jun; 175(2):443-449. PubMed ID: 30756284
[TBL] [Abstract][Full Text] [Related]
14. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Graeser MK; Engel C; Rhiem K; Gadzicki D; Bick U; Kast K; Froster UG; Schlehe B; Bechtold A; Arnold N; Preisler-Adams S; Nestle-Kraemling C; Zaino M; Loeffler M; Kiechle M; Meindl A; Varga D; Schmutzler RK
J Clin Oncol; 2009 Dec; 27(35):5887-92. PubMed ID: 19858402
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
Phillips KA; Milne RL; Rookus MA; Daly MB; Antoniou AC; Peock S; Frost D; Easton DF; Ellis S; Friedlander ML; Buys SS; Andrieu N; Noguès C; Stoppa-Lyonnet D; Bonadona V; Pujol P; McLachlan SA; John EM; Hooning MJ; Seynaeve C; Tollenaar RA; Goldgar DE; Terry MB; Caldes T; Weideman PC; Andrulis IL; Singer CF; Birch K; Simard J; Southey MC; Olsson HL; Jakubowska A; Olah E; Gerdes AM; Foretova L; Hopper JL
J Clin Oncol; 2013 Sep; 31(25):3091-9. PubMed ID: 23918944
[TBL] [Abstract][Full Text] [Related]
16. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers.
van Sprundel TC; Schmidt MK; Rookus MA; Brohet R; van Asperen CJ; Rutgers EJ; Van't Veer LJ; Tollenaar RA
Br J Cancer; 2005 Aug; 93(3):287-92. PubMed ID: 16052221
[TBL] [Abstract][Full Text] [Related]
17. [Genetic test and prophylactic treatment in breast cancer families].
Miyoshi Y; Noguchi S
Gan To Kagaku Ryoho; 2002 Apr; 29(4):512-22. PubMed ID: 11977534
[TBL] [Abstract][Full Text] [Related]
18. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.
Malone KE; Begg CB; Haile RW; Borg A; Concannon P; Tellhed L; Xue S; Teraoka S; Bernstein L; Capanu M; Reiner AS; Riedel ER; Thomas DC; Mellemkjaer L; Lynch CF; Boice JD; Anton-Culver H; Bernstein JL
J Clin Oncol; 2010 May; 28(14):2404-10. PubMed ID: 20368571
[TBL] [Abstract][Full Text] [Related]
19. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
20. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
